CIK 0001453687
- Non-accelerated filer
- Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-01 | Brunn Carsten President and CEO | Option exercise · Restricted Stock Units | −10,938 | 21,875 | ||
| 2022-05-09 | BARABE TIMOTHY C Director | Purchase | +50,000 | $0.77 | $39K | 250,013 |
| 2022-04-11 | SPRINGER TIMOTHY A Director | Purchase | +6,681,600 | 29,868,490 | ||
| 2022-04-11 | SPRINGER TIMOTHY A Director | Grant or award · Warrant (right to buy) | +5,011,200 | 5,011,200 | ||
| 2022-03-02 | Brunn Carsten President and CEO | Sale | −5,443 | $1.81 | $10K | 523,452 |
| 2022-03-01 | Brunn Carsten President and CEO | Option exercise | +10,937 | 528,895 | ||
| 2022-03-01 | Brunn Carsten President and CEO | Option exercise · Restricted Stock Units | −10,937 | 32,813 | ||
| 2022-01-14 | BARABE TIMOTHY C Director | Option exercise | +10,000 | $2.10 | $21K | 200,013 |
| 2022-01-14 | BARABE TIMOTHY C Director | Option exercise · Stock Option (Right to Buy) | −10,000 | $2.10 | $21K | 0 |
| 2022-01-05 | TRABER PETER G Chief Medical Officer | Sale | −3,226 | $3.09 | $10K | 251,355 |
| 2022-01-05 | Kishimoto Takashi Kei Chief Scientific Officer | Sale | −3,416 | $3.09 | $11K | 268,353 |
| 2022-01-05 | Johnston Lloyd P. Chief Operations Officer | Sale | −3,416 | $3.09 | $11K | 175,299 |
| 2022-01-05 | Brunn Carsten President and CEO | Sale | −13,597 | $3.09 | $42K | 517,958 |
| 2022-01-03 | ZENNER PATRICK J Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-03 | TRABER PETER G Chief Medical Officer | Grant or award | +90,200 | 254,581 | ||
| 2022-01-03 | TRABER PETER G Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +415,900 | 415,900 | ||
| 2022-01-03 | Tan Kevin Chief Financial Officer | Grant or award | +72,000 | 77,000 | ||
| 2022-01-03 | Tan Kevin Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +340,000 | 340,000 | ||
| 2022-01-03 | SPRINGER TIMOTHY A Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-03 | Sallin Aymeric Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 |
Page 21 of 25 · 495 trades